Price Action To Observe: What Next for GlaxoSmithKline plc (ADR) Stock After Today’s Huge Increase?

Price Action To Observe: What Next for GlaxoSmithKline plc (ADR) Stock After Today's Huge Increase?

The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) is a huge mover today! About 1.79M shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 11.54% since April 22, 2016 and is downtrending. It has underperformed by 16.95% the S&P500.
The move comes after 6 months positive chart setup for the $94.58 billion company. It was reported on Nov, 25 by Barchart.com. We have $40.09 PT which if reached, will make NYSE:GSK worth $2.84 billion more.

Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on February, 1. They expect $0.63 earnings per share, up 14.55% or $0.08 from last year’s $0.55 per share. GSK’s profit will be $1.53 billion for 15.44 P/E if the $0.63 EPS becomes a reality. After $0.83 actual earnings per share reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts -24.10% negative EPS growth.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The rating was upgraded by Bank of America to “Neutral” on Tuesday, September 8. As per Monday, October 12, the company rating was upgraded by JP Morgan. The company was upgraded on Tuesday, September 15 by BNP Paribas. The firm has “Hold” rating by Cantor Fitzgerald given on Friday, February 26. The firm has “Buy” rating given on Monday, December 7 by Argus Research. BNP Paribas downgraded the stock to “Underperform” rating in Wednesday, September 14 report. The stock has “Buy” rating given by Investec on Thursday, October 20. The rating was upgraded by Jefferies on Thursday, July 14 to “Buy”. Credit Suisse upgraded the stock to “Neutral” rating in Tuesday, October 20 report. Bryan Garnier & Cie upgraded the stock to “Buy” rating in Wednesday, January 27 report.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”

Another recent and important GlaxoSmithKline plc (ADR) (NYSE:GSK) news was published by Businessfinancenews.com which published an article titled: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment